Skip to main content
SpringerLink
Log in

Genitourinary Tumors

  • Chapter
  • First Online:
Genomic Medicine

  • 974 Accesses

Abstract

Neoplasms of the prostate and bladder are among the most common solid tumors. Recent genomic advances have contributed to our understanding of the key driver genetic alterations in these malignancies offering new opportunities for targeted therapy. Novel molecular classifications have been suggested.

This chapter lists salient predictive and prognostic biomarkers in prostate cancer and urothelial neoplasms as well as molecular approaches examining eligibility for therapeutic targets and novel immunotherapy strategies. A summary of noninvasive urine-based assays for early detection and surveillance of urothelial carcinoma is forwarded. The potential practical implications of a recently proposed genomic-based taxonomy for bladder cancer is discussed. Practice-based take-home messages are emphasized.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.

    Article  Google Scholar 

  2. Weier C, Haffner MC, Mosbruger T, Esopi DM, Hicks J, Zheng Q, et al. Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer. J Pathol. 2013;230:174–83.

    Article  CAS  Google Scholar 

  3. Netto GJ. Clinical applications of recent molecular advances in urologic malignancies: no longer chasing a “mirage”? Adv Anat Pathol. 2013;20:175–203.

    Article  CAS  Google Scholar 

  4. Kote-Jarai Z, Mikropoulos C, Leongamornlert DA, Dadaev T, Tymrakiewicz M, Saunders EJ, et al. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. Ann Oncol. 2015;26:756–61.

    Article  CAS  Google Scholar 

  5. Bryant HE. The clinical impact of BRCA2 loss in prostate cancer. Eur Urol. 2016;69:996–7.

    Article  CAS  Google Scholar 

  6. Ryan S, Jenkins MA, Win AK. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23:437–49.

    Article  CAS  Google Scholar 

  7. Network NCC. National Comprehensive Cancer Network (NCCN): prostate. Cancer. 2018. https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

  8. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12:245–55.

    Article  CAS  Google Scholar 

  9. Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, et al. Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics. 2013;14:690.

    Article  CAS  Google Scholar 

  10. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One. 2013;8:e66855.

    Article  CAS  Google Scholar 

  11. Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol. 2013;190:2047.

    Article  CAS  Google Scholar 

  12. Blume-Jensen P, Berman DM, Rimm DL, Shipitsin M, Putzi M, Nifong TP, et al. Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin Cancer Res. 2015;21:2591–600.

    Article  CAS  Google Scholar 

  13. Network CGAR. The molecular taxonomy of primary prostate cancer. Cell. 2015;163:1011–25.

    Article  Google Scholar 

  14. Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. 2017;2017 https://doi.org/10.1200/PO.17.00029.

  15. Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, et al. Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide. Eur Urol. 2018;74:218–25.

    Article  CAS  Google Scholar 

  16. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443–53.

    Article  CAS  Google Scholar 

  17. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;162:454.

    Article  CAS  Google Scholar 

  18. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33:244–50.

    Article  CAS  Google Scholar 

  19. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–13.

    Article  CAS  Google Scholar 

  20. Imyanitov EN, Moiseyenko VM. Drug therapy for hereditary cancers. Hered Cancer Clin Pract. 2011;9:5.

    Article  CAS  Google Scholar 

  21. Chamie K, Litwin MS, Bassett JC, Daskivich TJ, Lai J, Hanley JM, et al. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer. 2013;119:3219–27.

    Article  Google Scholar 

  22. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 2000;164:680–4.

    Article  CAS  Google Scholar 

  23. Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447–61.

    Article  Google Scholar 

  24. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Joint Guideline. 2016. http://www.auanet.org/guidelines/bladder-cancer-non-muscle-invasive-(2016).

  25. Network NCC. NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer. 2018. https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf.

  26. Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO Guideline. 2017. http://www.auanet.org/guidelines/bladder-cancer-non-metastatic-muscle-invasive-(2017).

  27. Witjes JA (Chair), Bruins M, Compérat E, Cowan NC, Gakis G, Hernández V, Lebret T, Lorch A, Ribal MJ (Vice-chair), van der Heijden AG, Veskimäe E. European Association of Urology (EAU) Guideline: muscle-invasive and metastatic bladder cancer. 2018. http://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/.

  28. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. New Engl J Med. 2017;376:1015–26.

    Article  CAS  Google Scholar 

  29. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67–76.

    Article  CAS  Google Scholar 

  30. Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483–92.

    Article  CAS  Google Scholar 

  31. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 2005;66:35–63.

    Article  Google Scholar 

  32. Guo A, Wang X, Gao L, Shi J, Sun C, Wan Z. Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: a meta-analysis. Can Urol Assoc J. 2014;8:E347–52.

    Article  Google Scholar 

  33. Chou R, Gore JL, Buckley D, Fu R, Gustafson K, Griffin JC, et al. Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis. Ann Intern Med. 2015;163:922–31.

    Article  Google Scholar 

  34. Smith ZL, Guzzo TJ. Urinary markers for bladder cancer. F1000Prime Rep. 2013;5:21.

    Article  Google Scholar 

  35. O’Sullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, Cambridge L, et al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol. 2012;188:741–7.

    Article  Google Scholar 

  36. Wang Z, Que H, Suo C, Han Z, Tao J, Huang Z, et al. Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis. Oncotarget. 2017;8:100648–56.

    PubMed  PubMed Central  Google Scholar 

  37. He H, Han C, Hao L, Zang G. ImmunoCyt test compared to cytology in the diagnosis of bladder cancer: a meta-analysis. Oncol Lett. 2016;12:83–8.

    Article  CAS  Google Scholar 

  38. Lavery HJ, Zaharieva B, McFaddin A, Heerema N, Pohar KS. A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection. BMC Cancer. 2017;17:247.

    Article  Google Scholar 

  39. Feber A, Dhami P, Dong L, de Winter P, Tan WS, Martinez-Fernandez M, et al. UroMark-a urinary biomarker assay for the detection of bladder cancer. Clin Epigenetics. 2017;9:8.

    Article  Google Scholar 

  40. Lotan Y, O’Sullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C, et al. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urol Oncol. 2017;35:531.e15–22.

    Article  Google Scholar 

  41. Springer SU, Chen CH, Rodriguez Pena MDC, Li L, Douville C, Wang Y, et al. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. Elife. 2018;7. pii: e32143.

    Google Scholar 

  42. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540–56 e25.

    Article  CAS  Google Scholar 

  43. Netto GJ, Tafe LJ. Emerging bladder cancer biomarkers and targets of therapy. Urol Clin North Am. 2016;43:63–76.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA

    Marie-Lisa Eich & George J. Netto

Authors
  1. Marie-Lisa Eich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George J. Netto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George J. Netto .

Editor information

Editors and Affiliations

  1. Dartmouth–Hitchcock Medical Center, Lebanon, NH, USA

    Laura J. Tafe

  2. Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Maria E. Arcila

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Eich, ML., Netto, G.J. (2020). Genitourinary Tumors. In: Tafe, L., Arcila, M. (eds) Genomic Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-22922-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-22922-1_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-22921-4

  • Online ISBN: 978-3-030-22922-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation